GigaGen Publishes Study Demonstrating Optimal Method for Selecting OX40 Therapeutic Candidates from Antibody Repertoires

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study showing how it adapted its Surge™ antibody discovery and engineering platform to improve selection of OX40 agonists. The study has been published online in the peer-reviewed scientific journal, Antibodies, as part of the special issue Antibody Repertoire Mining for Immune Profiling, Antibody Discovery and Vaccine Design.

Read the full press release.

GigaGen Promotes Adam Adler, Ph.D., to Chief Scientific Officer

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the promotion of Adam Adler, Ph.D., to Chief Scientific Officer (CSO). Previously, Dr. Adler was the company’s Vice President of Research and Development. In addition, Gigagen has promoted Rena Mizrahi, Ph.D to Vice President of Process Development and Catherine Medina to Vice President of Operations.

Read the full press release.

GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Erica Stone, Ph.D., has joined the company as director, immuno-oncology.

“We welcome award-winning immunologist Dr. Stone to the GigaGen team,” said Dave Johnson, Ph.D., CEO of GigaGen. “Dr. Stone brings with her a deep understanding of the tumor microenvironment and checkpoint inhibitors that is perfectly paired with our novel antibody discovery and engineering platform, Surge. Surge enables us to uncover new antibodies that have historically been missed by traditional discovery methods such as hybridoma, and with Dr. Stone’s expertise we look forward to identifying immuno-oncology drug candidates with the greatest potential to improve patient treatment.”

Read the full press release.

 

GigaGen CEO David Johnson to Present at 2018 Antibody Engineering & Therapeutics Meeting

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2018 Antibody Engineering & Therapeutics Meeting. Dr. Johnson’s presentation will take place at 3:15 p.m. PST on December 9, 2018, at the Manchester Grand Hyatt in San Diego, Calif.

Read the full press release.

GigaGen CEO David Johnson to Present on Development of Recombinant Polyclonal Therapies for Infectious Disease at 10th Annual PEGS Summit Europe

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the development of highly diverse, functional antibodies for infectious disease utilizing Surge technology at the 10th Annual Protein & Antibody Engineering Summit (PEGS) in Europe. Dr. Johnson’s invited podium presentation is titled “Microfluidics and Genomics for Polyclonal and Monoclonal Antibody Drugs for Infectious Disease” and will take place during the Engineering Antibodies conference at 11:15 a.m. GMT on November 13, 2018, at the Libson Congress Center in Libson, Portugal.

Read the full press release.

 

GigaGen to Present Data on Immuno-Oncology Pipeline at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Adam Adler, Ph.D., Vice President of Research and Development, will present on the antibody drug candidates discovered by the company’s industry-leading Surge technology against 17 unique immuno-oncology targets. The conference takes place November 7-11, 2018 at the Walter E. Washington Convention Center in Washington, D.C.

Read the full press release.

 

Genetic Engineering & Biotechnology News: Microfluidic dragnet catches most-wanted antibodies – GigaGen exhaustively interrogates antibodies to find drug candidates

,

“Scrappy.” That’s a one-word summation of GigaGen’s approach to both the business and science of biotech.

“When you’re a new company, you have to be scrappy and clever. When I founded GigaGen in 2011, I didn’t have a big war chest of money, so I had to find a way to be competitive. That’s central for survival,” says Dave Johnson, Ph.D., CEO of GigaGen.

Surge Workflow Performs Complete Interrogation

“Competitive” means “innovative” to Dr. Johnson. That drive to innovate resulted in a proprietary workflow called Surge, which he says not only interrogates every antibody in the immune system, but does it 10 times faster than other technologies.
Read the full story.

GigaGen to Present Data on Recombinant Hyperimmune Gammaglobulin at the 18th Biennial Meeting of the European Society for Immunodeficiencies

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 18th Biennial Meeting of the European Society for Immunodeficiencies (ESID). Rena Mizrahi, Ph.D., director of protein engineering, will present on the company’s proprietary recombinant hyperimmune gammaglobulin program. The conference takes place October 24-27, 2018, at the Centro de Congressos de Lisboa in Libson, Portugal.

Read the full story.

 

Drug Discovery News: GigaGen CEO Dave Johnson, PhD, discusses I/O product development and impact of NIH grant support on company growth

,

The National Institutes of Health (NIH) is a household name in the drug discovery and development industry. Among the NIH’s many recipients is South San Francisco, Calif.-based GigaGen, a biotherapeutics company. GigaGen’s CEO, Dr. Dave Johnson, took some time to talk with us about how NIH funding and participation in the I-Corps commercialization program helped the company build momentum and secure additional funding and partner support.

Read the full story.

 

GigaGen CEO Dave Johnson interviewed by Moira Gunn on Biotech Nation Radio

,

Listen to Moira Gunn’s interview with GigaGen CEO Dave Johnson, PhD, on developing next generation I/O drugs to fight cancer on  Biotech Nation Radio